title: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
abstract: Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II-IV) and transplant-related mortality were significantly decreased (P=0.01 and P<10(-4), respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.
authors.affiliation: EA1638 Université Paris 6, Acute Leukemia Working Party and European Group of Blood and Marrow Transplant Office Paris, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Aoudjhane
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.forename: N C
authors.initials: NC
authors.lastname: Gorin
authors.forename: A
authors.initials: A
authors.lastname: Shimoni
authors.forename: T
authors.initials: T
authors.lastname: Ruutu
authors.forename: H-J
authors.initials: HJ
authors.lastname: Kolb
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: J M
authors.initials: JM
authors.lastname: Boiron
authors.forename: J L
authors.initials: JL
authors.lastname: Yin
authors.forename: J
authors.initials: J
authors.lastname: Finke
authors.forename: H
authors.initials: H
authors.lastname: Shouten
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: M
authors.initials: M
authors.lastname: Falda
authors.forename: A A
authors.initials: AA
authors.lastname: Fauser
authors.forename: J
authors.initials: J
authors.lastname: Esteve
authors.forename: E
authors.initials: E
authors.lastname: Polge
authors.forename: S
authors.initials: S
authors.lastname: Slavin
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.forename: V
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000368:Aged; D002423:Cause of Death; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012008:Recurrence; D012042:Registries; D012189:Retrospective Studies; D035781:Siblings; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome